|Visual assessment of posterior atrophy development of a MRI rating scale.|
|Jump to Full Text|
|PMID: 21805370 Owner: NLM Status: MEDLINE|
|OBJECTIVE: To develop a visual rating scale for posterior atrophy (PA) assessment and to analyse whether this scale aids in the discrimination between Alzheimer's disease (AD) and other dementias.
METHODS: Magnetic resonance imaging of 118 memory clinic patients were analysed for PA (range 0-3), medial temporal lobe atrophy (MTA) (range 0-4) and global cortical atrophy (range 0-3) by different raters. Weighted-kappas were calculated for inter- and intra-rater agreement. Relationships between PA and MTA with the MMSE and age were estimated with linear-regression analysis.
RESULTS: Intra-rater agreement ranged between 0.93 and 0.95 and inter-rater agreement between 0.65 and 0.84. Mean PA scores were higher in AD compared to controls (1.6 ± 0.9 and 0.6 ± 0.7, p < 0.01), and other dementias (0.8 ± 0.8, p < 0.01). PA was not associated with age compared to MTA (B = 1.1 (0.8) versus B = 3.1 (0.7), p < 0.01)). PA and MTA were independently negatively associated with the MMSE (B = -1.6 (0.5), p < 0.01 versus B = -1.4 (0.5), p < 0.01).
CONCLUSION: This robust and reproducible scale for PA assessment conveys independent information in a clinical setting and may be useful in the discrimination of AD from other dementias.
|Esther L G E Koedam; Manja Lehmann; Wiesje M van der Flier; Philip Scheltens; Yolande A L Pijnenburg; Nick Fox; Frederik Barkhof; Mike P Wattjes|
|Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2011-07-31|
|Title: European radiology Volume: 21 ISSN: 1432-1084 ISO Abbreviation: Eur Radiol Publication Date: 2011 Dec|
|Created Date: 2011-11-17 Completed Date: 2012-02-27 Revised Date: 2013-06-28|
Medline Journal Info:
|Nlm Unique ID: 9114774 Medline TA: Eur Radiol Country: Germany|
|Languages: eng Pagination: 2618-25 Citation Subset: IM|
|Department of Neurology and Alzheimer Centre, VU University Medical Centre, PO Box 7057, 1007 MB, Amsterdam, The Netherlands. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Atrophy / diagnosis
Cognition Disorders / diagnosis*, pathology
Magnetic Resonance Imaging* / methods
Parietal Lobe / pathology*
|//Medical Research Council|
Journal ID (nlm-ta): Eur Radiol
Publisher: Springer-Verlag, Berlin/Heidelberg
© The Author(s) 2011
Received Day: 18 Month: 3 Year: 2011
Revision Received Day: 20 Month: 5 Year: 2011
Accepted Day: 22 Month: 6 Year: 2011
Electronic publication date: Day: 31 Month: 7 Year: 2011
pmc-release publication date: Day: 31 Month: 7 Year: 2011
Print publication date: Month: 12 Year: 2011
Volume: 21 Issue: 12
First Page: 2618 Last Page: 2625
PubMed Id: 21805370
Publisher Id: 2205
|Visual assessment of posterior atrophy development of a MRI rating scale|
|Esther L. G. E. Koedam1||
Address: +31-20-4440685 +31-20-4440715 firstname.lastname@example.org
|Wiesje M. van der Flier13||
|Yolande A. L. Pijnenburg1||
|Mike P. Wattjes2||
1Department of Neurology and Alzheimer Centre, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
2Department of Radiology, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, the Netherlands
3Department Epidemiology and Biostatistics, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, the Netherlands
4Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK
Alzheimer’s disease (AD) has been considered clinically homogenous and characterized by progressive memory impairment followed by global cognitive decline . The clinical diagnosis of AD depends largely on the presenting cognitive profile. However, atypical focal presentations of AD may be more common than previously thought, which can make a clinical diagnosis difficult [1–3]. Neuroimaging, particularly magnetic resonance (MR) imaging, has an established role in excluding other, potentially treatable diagnoses, but also increasingly recognized potential to support a clinical diagnosis of AD by identifying certain atrophy patterns [4, 5]. AD is typically associated with medial temporal lobe atrophy (MTA) [6–9]. The presence of MTA on MR imaging improves the discrimination of AD from healthy controls and predicts progression to dementia in patients with mild cognitive impairment (MCI) [9, 10]. Visual MTA rating based on established rating scales, has proven to be useful for a good and reproducible assessment in clinical practice and correlates well with volumetric assessments [11, 12]. However, MTA is also present in other dementias, for example Frontotemporal lobe degeneration (FTLD), vascular dementia (VaD) and dementia with Lewy bodies (DLB) and may been seen in normal aging [13–18]. Furthermore, younger AD patients often show relatively less (or no) MTA at presentation .
Occasionally, AD patients present with a striking posterior atrophy pattern- often referred to as posterior cortical atrophy. Benson et al. were the first describing patients with evidence of posterior cerebral involvement and prominent visual problems and suggested possible underlying AD . Early posterior cerebral involvement is emerging as an important aspect of AD, more generally with dysfunction and atrophy of the posterior cingulate gyrus, precuneus and parietal lobes, being perhaps a particular feature of early-onset (<65 years) AD (EOAD) [3, 19, 21–27]. Posterior atrophy (PA) appears to be characteristic of AD in patients with typical and atypical clinical presentations and may assist in the clinical distinction of AD from Frontotemporal lobar degeneration (FTLD) [28, 29]. Moreover, combined with relative sparing of the medial temporal lobe, PA has found to be characteristic for patients with atypical clinical presentations [3, 25, 30].
Limited data is available about the clinical relevance of PA and no visual rating scale is currently available to measure atrophy in the posterior regions, hampering systematic evaluation of PA. The purpose of this study was to develop a robust visual rating scale for PA assessment and evaluate intra- and inter-observer agreement. The second aim was to investigate the clinical relevance of PA, by comparing the degree of PA in AD, controls and other dementias and investigate the relationship with age and the mini-mental state examination (MMSE) .
This study was conducted at our memory clinic and approved by the local institutional review board. Written informed consent was obtained from all participants.
We selected 120 patients from our memory clinic population based on their clinical diagnosis. The selection included 60 AD patients (35 EOAD (onset <65 years) and 25 late-onset AD), 20 age-matched patients with other dementias (10 FTLD and 10 DLB patients) and 40 age-matched patients with subjective memory complaints, without cognitive impairment. The group of other dementias did not include patients with vascular dementia, characterized by severe vascular abnormalities on MR imaging, since this could be of influence on PA measurement. The diagnostic procedure consisted of a standard battery of investigations including a patient and informant-based medical history, physical and neurological examination including the MMSE and multisequence MR imaging. The clinical diagnosis of probable AD, FTLD or DLB was made according to current criteria by a multidisciplinary team, including a neurologist, psychiatrist, neurophysiologist, neuropsychologist and specialized nurse [32–34]. The patients’ diagnosis was established on clinical criteria and not on basis of their imaging findings. Imaging findings did not change a patient’s diagnosis in our study group.
MR imaging was performed using 3.0 T MR (Signa HDxt, General Electric, Milwaukee). Mean time between MR imaging and diagnosis was 0.2 ±1 months. All subjects were examined according to a standard dementia MRI protocol: sagittal T1-weighted 3D fast spoiled gradient echo (FSPGR) sequences (field of view (FOV) = 250 mm; matrix = 256 × 256; 1 mm slices; echo time = 3 ms; repetition time = 7.8 ms; inversion time = 450 ms; one signal acquired), 3D fluid-attenuated inversion recovery (FLAIR) (FOV = 250 mm; matrix = 224 × 224; 1 mm slices; echo time = 125 ms; repetition time = 8,000 ms; inversion time = 2,349 ms; echo train length 230, one signal acquired) and axial fast spin-echo T2/PD sequences (FOV = 250 mm; matrix = 384 × 384; 3 mm slices; echo time = 20/109 ms; repetition time = 8,240 ms; echo train length 24, two signals acquired). Multiplanar (MPR) reconstructions of 3D-T1-weighted sequences were performed in sagittal (5 mm) and oblique-coronal orientations (3 mm slices perpendicular to the long axis of the hippocampus), using a 5 mm section thickness. MPR reconstructions of 3D-FLAIR images were performed in transverse orientation using a 3 mm section thickness.
To define the areas included in the scale, we evaluated 25 MR examinations from probable AD patients with a wide range of atrophy and determined the most affected posterior regions. Secondly, we assessed these areas in 10 controls, to determine whether these areas were more affected in AD patients and therefore able to represent PA. Finally, taking into account those regions mentioned in literature, the following anatomical regions were selected: the posterior cingulate sulcus, precuneus, parieto-occipital sulcus and the cortex of the parietal lobes. The MR examinations used to determine which posterior regions to rate were not further used in this study, to avoid any circularity.
To assess PA we designed a 4-point rating scale (0 = no atrophy; 1 = mild widening of the sulci without evident volume loss of the gyri; 2 = substantial widening of the sulci and volume loss of the gyri; grade 3 = severe end-stage atrophy). The overall score based on the presence of atrophy in sagittal, axial and coronal orientation, was assessed for left and right separately on sagittal and coronal MPR sections of the T1-weighted sequence and axial MPR sections of the FLAIR sequence.
The following anatomical landmarks were rated in three different orientations:
- sagittal orientation: widening of the posterior cingulate- and parieto-occipital sulcus, and atrophy of the precuneus on left and right by considering paramedian-sagittal images.
- axial orientation: widening of the posterior cingulate sulcus and sulcal dilatation in parietal lobes on axial images.
- coronal orientation: widening of the posterior cingulate sulcus and parietal lobes on coronal images.
Grade 0 represents a closed posterior cingulate- and parieto-occipital sulcus and closed sulci of the parietal lobes and precuneus. Grade 1 includes a mild widening of the posterior cingulate- and parieto-occipital sulcus, with mild atrophy of the parietal lobes and precuneus. Grade 2 shows substantial widening of the posterior cingulate- and parieto-occipital sulcus, with substantial atrophy of the parietal lobes and precuneus. Grade 3 represents end-stage atrophy with evident widening of both sulci and knife-blade atrophy of the parietal lobes and precuneus (the different grades of atrophy are shown in Figure 1). In case of different scores on different orientations (e.g. score 1 on sagittal direction and score 2 on axial direction), the highest score was considered.
All 120 MR examinations were rated for PA by three different raters (rater 1: neuroradiologist, 8-year experience in imaging in dementia, rater 2: MD working as PhD-student and rater 3: PhD-student, both 3-year experience in imaging in dementia). All raters were blinded for the clinical diagnosis and paraclinical tests. Twenty-nine MR examinations were rated twice by two observers (rater 1 and 2) to assess intra-rater agreement. All MR examinations were rated for MTA using a 5-point rating scale (0–4) and for global cortical atrophy (GCA) by two raters (rater 1 and 2) using a 4-point (0–3) rating scale.[9, 35] GCA was assessed on axial MPR sections of the FLAIR sequence and MTA was assessed on oblique-coronal MPR sections of the T1-weighted sequence.
For statistical analysis we used averaged scores of the left and right hemisphere for the posterior scale and MTA scale. Basic demographic data were examined using Chi-square tests for categorical data and t-tests for continuous data. To analyse differences in mean atrophy scores between the groups, scores of one rater (rater 1) were used. To quantify inter- and intra-observer agreement we calculated weighted-kappa’s between each pair of observers and between the first and second session of two raters separately. For weighted-kappa values, degree of agreement was defined according to Landis and Koch .
Linear-regression analysis was used to analyse relationships between scores on each visual rating scale and age and MMSE score. In the first model relationships of each visual rating scale (independent variable) with either MMSE or age (dependent variable) were assessed unadjusted. In the second model the same relationships were assessed, corrected for age and sex in the analysis with the MMSE and corrected for sex in the analysis with age. In the third model both visual rating scales were entered simultaneously, together with the same covariates. Results are presented as linear-regression coefficients with standard error, B (SE). Statistical significance was set at p < 0.05.
Two controls were excluded, since sagittal T1-weighted sequences were missing, resulting in a total group of 118 patients (60 AD, 20 other dementias and 38 controls).
Table 1 shows demographical and imaging characteristics of the study population. The groups were similar with respect to age. Sex was equally distributed within AD patients and controls (roughly 50% female), whereas women made up 25% of other dementias patients (p < 0.05). Disease duration (time between first symptoms and diagnosis) did not differ between AD and other dementias. Mean MTA scores were higher in AD compared with controls (1.3 ± 1.0 versus 0.4 ± 0.7, p < 0.01), but did not differ from other dementias (1.2 ± 1.0). GCA scores were higher in AD compared with controls (1.1 ± 0.7 versus 0.2 ± 0.5, p < 0.01) and other dementias (0.7 ± 0.7, p < 0.05).
Mean scores on the PA rating scale were higher in AD compared with controls (1.6 ± 0.9 and 0.6 ± 0.7, p < 0.01) and other dementias (0.8 ± 0.8, p < 0.01). PA scores did not differ between other dementias and controls.
Intra-rater agreement (determined in 29 MR examinations for 2 raters) for PA was excellent with a weighted-kappa value of 0.93 (rater 1) and 0.95 (rater 2). Inter-rater agreement (determined in 118 examinations for 3 rater pairings) was best between rater 1 and 2, with a value of 0.84, followed by a value of 0.70 between rater 2 and 3 and lowest between rater 1 and 3, with a value of 0.65. The average value for inter-rater agreement (0.73) was good. Intra-rater agreement for MTA varied between 0.91 and 0.95, whereas values for inter-rater agreement varied between 0.82 (rater 1 and 3) and 0.90 (rater 1 and 2 and rater 2 and 3) (Table 2). GCA was only rated by two raters (rater 1 and 2), intra-rater agreement was 0.85 for both raters and inter-rater agreement was 0.70.
In a separate analysis we investigated relationships between PA and MTA with either age or MMSE across the entire group (Table 3). Higher ratings of MTA were associated with older age (B = 3.1 (0.7), p < 0.01) and lower MMSE scores (B = −2.0 (0.5), p < 0.01). By contrast, PA was not related to age, but there was an equally strong relationship with MMSE scores (B = −1.8 (0.5), p < 0.01)). These results remained essentially unchanged when both scales were entered into the same model, illustrating their independent effects on cognitive deterioration.
To further investigate how MTA and PA contribute to AD, we investigated the degree of MTA and PA in AD, controls and other dementias (Table 4). We therefore dichotomized scores for MTA and PA, with an average score of >1 being considered abnormal for both rating scales. Most of the controls had normal scores (≤1) for MTA and PA (N = 33, 88%). A minority had either MTA or PA, but none of the controls had abnormal scores (>1) for both regions. In AD, 28% had prominent PA (scores >1) without evident MTA, whereas only 15% had prominent MTA (scores >1) without evident PA. Minimal MTA and PA was found in 27% of the AD patients. The sensitivity of PA for AD was 58%, with a specificity of 95%, whereas MTA had a sensitivity of 45% with a specificity of 92%. Combining MTA and PA (combining patients with either MTA or PA, or a combination of both) increased sensitivity to 73% and slightly decreased specificity to 87%.
Most other dementia patients had normal scores for MTA and PA (N = 9, 45%).
When we looked at early- and late-onset AD separately, it became obvious that in late-onset AD approximately the same proportion had either prominent PA or MTA (20% versus 16%). However, in EOAD, 34% had prominent PA, whereas only 14% had prominent MTA. Disease duration did not differ between early- and late-onset AD (3.3 years ± 1.9 versus 3.0 years ± 1.6, p = 0.5).
PA is seen in a substantial proportion of AD patients, perhaps particularly in those with an early onset. Because of the complexity of anatomy and variability in posterior regions, this atrophy may be less obvious to inspection than MTA. Moreover, a visual rating scale for PA has been lacking. With this study we aimed to develop a robust visual rating scale, to detect the wide range and complexity of PA. We found that agreement on visual assessment of PA varied between good and excellent. Furthermore, higher PA scores were found in AD compared to controls and other dementias and therefore the scale may be useful in the discrimination between AD and other dementias.
Several studies have shown that the precuneus, parietal lobes and posterior cingulate gyrus are frequently affected in (younger) AD patients and our visual rating scale was designed to include these regions [3, 19, 21–26].
Visual rating of atrophy has shown to be a quick and reproducible method to assess the degree of atrophy in a clinical setting, compared to more labour intensive techniques like volumetric analysis. For applicability in different clinical settings or by different raters, good inter- and intra-rater agreement is essential. Visual rating of MTA using a 5-point scale has become fairly established and has shown fair to good inter-rater agreement [9, 12, 37]. Visual rating of GCA seems harder to perform reliably between different raters, while despite moderate to good intra-rater agreement, poor inter-rater agreement has been reported . Our PA rating scale varied between good and excellent inter- and intra-rater agreement even between raters with different degrees of expertise, suggesting its usefulness in a clinical setting as an aid in assessment of PA. However, degree of agreement was lower for PA compared to MTA (Table 2), which could be due to the fact that visual assessment of MTA is applied for many years in our memory clinic and raters gained much experience. Visual assessment of PA on the contrary has not been done before and our study is the first to assess the applicability of visual assessment of PA in a clinical setting.
MTA is one of the most important markers of AD on MR imaging. In the newly developed AD research criteria, presence of early episodic memory decline and MTA is sufficient for a diagnosis of prodromal AD . MTA, however, has been described in other dementias, which makes MTA by itself less useful in the discrimination of AD from other dementias [13–16, 18]. Furthermore, there is an overlap in hippocampal volumes with normal aging, which could make the interpretation of MTA more difficult in older subjects .
There is increasing evidence that posterior brain regions are relatively more affected in EOAD and medial temporal lobe structures may be less involved [19, 21–24, 26]. Several clinico-pathological studies have reported involvement of the posterior cingulate gyrus, parieto-occipital-, and temporoparietal cortex in AD patients with typical as well as atypical clinical presentations, although the combination with relative sparing of the medial temporal lobe occurs especially in patients presenting without prominent memory impairment [3, 25, 28–30]. PA may be under-recognized, as clinicians may be unaware of this relatively subtle MR imaging characteristic of AD. Our visual assessment of PA was able to discriminate AD from controls and other dementias, whereas MTA failed to discriminate between AD and other dementias. We found that a considerable proportion of AD patients (28%) had prominent PA and mild or absent MTA, whereas only 15% had prominent MTA and mild or absent PA. Furthermore, combining MTA and PA increased the sensitivity for AD. This underlines the importance of evaluating PA in the diagnostic work-up of dementia.
Earlier studies showed that PA was more prominent in younger AD patients [22, 26]. We found that the proportion of patients with predominant PA was higher in EOAD compared to late-onset AD (34% versus 20%). Furthermore, patients with only prominent PA were younger than patients with only prominent MTA, although this difference did not reach statistical significance. However, we did not find a direct relation between PA and age with linear-regression analysis.
A previous study has shown that MTA is correlated with memory deficits and lower MMSE scores in AD . PA seems to have clinical relevance as well, since PA was clearly associated with lower MMSE scores, independent of MTA. This is perhaps not surprising, given the importance of posterior (non-memory) aspects of the MMSE, such as calculation and visuospatial function.
A limitation of our study is lack of pathological confirmation of the diagnoses. We therefore cannot exclude other underlying abnormalities or mixed disease processes. However, all patients were carefully screened and fulfilled clinical criteria for the specific dementia types. It should be noted that our cohort consisted of relatively young AD patients, which could have influenced our results, since PA may be relatively more common in younger patients. Before generalisation of our results to older AD patients, further research is necessary to determine the prevalence of PA in large numbers of young and elderly AD patients and assess its discriminative power and the potential influence of age on its utility.
A considerable number of patients attending a memory clinic are not able to undergo MR imaging for any number of reasons (e.g. pacemaker, limited availability of MR imaging etc.) and computed tomography (CT) could be an alternative. Visual assessment of MTA has found to be comparable on CT and MR imaging and future work should address whether our rating scale is also applicable for CT .
In conclusion this study provides an easy applicable and robust visual rating scale to assess PA. Measurement of PA using this visual rating scale appears to add value in the discrimination of AD from controls and other dementias (FTLD and DLB) on MRI.
The authors wish to thank Dr. Dirk L. Knol, Department of Epidemiology and Biostatistics, VU University Medical Center Amsterdam for his statistical advice. NCF is supported by an MRC (UK) Senior Clinical Fellowship and holds a National Institute for Health Research (NIHR) senior investigator award. ML is supported by the Alzheimer’s Society.
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
|1..||Hodges JR. Alzheimer's centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspectsBrainYear: 20061292811282210.1093/brain/awl27517071920|
|2..||Alladi S,Xuereb J,Bak T,et al. Focal cortical presentations of Alzheimer's diseaseBrainYear: 20071302636264510.1093/brain/awm21317898010|
|3..||Galton CJ,Patterson K,Xuereb JH,et al. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 casesBrainYear: 200012348449810.1093/brain/123.3.48410686172|
|4..||Dubois B,Feldman HH,Jacova C,et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteriaLancet NeurolYear: 2007673474610.1016/S1474-4422(07)70178-317616482|
|5..||Scheltens PH. Structural neuroimaging of Alzheimer's disease and other dementiasAging (Milano)Year: 20011320320911442302|
|6..||Erkinjuntti T,Lee DH,Gao F,et al. Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer's diseaseArch NeurolYear: 1993503053108442711|
|7..||Jack CR Jr,Petersen RC,O'Brien PC,et al. MR-based hippocampal volumetry in the diagnosis of Alzheimer's diseaseNeurologyYear: 1992421831881734300|
|8..||Kesslak JP,Nalcioglu O,Cotman CW. Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's diseaseNeurologyYear: 19914151541985296|
|9..||Scheltens P,Leys D,Barkhof F,et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlatesJ Neurol Neurosurg PsychiatryYear: 19925596797210.1136/jnnp.55.10.9671431963|
|10..||Korf ES,Wahlund LO,Visser PJ,et al. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairmentNeurologyYear: 2004639410015249617|
|11..||Bresciani L,Rossi R,Testa C,et al. Visual assessment of medial temporal atrophy on MR films in Alzheimer's disease: comparison with volumetryAging Clin Exp ResYear: 20051781315847116|
|12..||Scheltens P,Launer LJ,Barkhof F,et al. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliabilityJ NeurolYear: 199524255756010.1007/BF008688078551316|
|13..||Barber R,Gholkar A,Scheltens P,et al. Medial temporal lobe atrophy on MRI in dementia with Lewy bodiesNeurologyYear: 1999521153115810214736|
|14..||Bastos-Leite AJ,Flier WM,Straaten EC,et al. The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementiaStrokeYear: 2007383182318510.1161/STROKEAHA.107.49010217962598|
|15..||Laakso MP,Partanen K,Riekkinen P,et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI studyNeurologyYear: 1996466786818618666|
|16..||Staekenborg SS,Straaten EC,Flier WM,et al. Small vessel versus large vessel vascular dementia: risk factors and MRI findingsJ NeurolYear: 20082551644165110.1007/s00415-008-0944-118677637|
|17..||Pol LA,Hensel A,Barkhof F,et al. Hippocampal atrophy in Alzheimer disease: age mattersNeurologyYear: 20066623623816434661|
|18..||Pol LA,Hensel A,Flier WM,et al. Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's diseaseJ Neurol Neurosurg PsychiatryYear: 20067743944210.1136/jnnp.2005.07534116306153|
|19..||Frisoni GB,Testa C,Sabattoli F,et al. Structural correlates of early and late onset Alzheimer's disease: voxel based morphometric studyJ Neurol Neurosurg PsychiatryYear: 20057611211410.1136/jnnp.2003.02987615608008|
|20..||Benson DF,Davis RJ,Snyder BD. Posterior cortical atrophyArch NeurolYear: 1988457897933390033|
|21..||Barnes J,Godbolt AK,Frost C,et al. Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLDNeurobiol AgingYear: 200728202810.1016/j.neurobiolaging.2005.11.01216406154|
|22..||Frisoni GB,Pievani M,Testa C,et al. The topography of grey matter involvement in early and late onset Alzheimer's diseaseBrainYear: 200713072073010.1093/brain/awl37717293358|
|23..||Ishii K,Kawachi T,Sasaki H,et al. Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score imagesAJNR Am J NeuroradiolYear: 20052633334015709131|
|24..||Jones BF,Barnes J,Uylings HB,et al. Differential regional atrophy of the cingulate gyrus in Alzheimer disease: a volumetric MRI studyCereb CortexYear: 2006161701170810.1093/cercor/bhj10516400164|
|25..||Josephs KA,Whitwell JL,Duffy JR,et al. Progressive aphasia secondary to Alzheimer disease vs FTLD pathologyNeurologyYear: 200870253410.1212/01.wnl.0000287073.12737.3518166704|
|26..||Karas G,Scheltens P,Rombouts S,et al. Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI studyNeuroradiologyYear: 20074996797610.1007/s00234-007-0269-217955233|
|27..||Scahill RI,Schott JM,Stevens JM,et al. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRIProc Natl Acad Sci USAYear: 2002994703470710.1073/pnas.05258739911930016|
|28..||Lehmann M,Rohrer JD,Clarkson MJ,et al. Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer's diseaseJ Alzheimers DisYear: 20102058759820182057|
|29..||Whitwell JL, Jack CR Jr, Przybelski SA et al (2009) Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2009.10.012|
|30..||Lehmann M,Crutch SJ,Ridgway GR,et al. Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer's diseaseNeurobiol AgingYear: 2009321466147610.1016/j.neurobiolaging.2009.08.01719781814|
|31..||Folstein MF,Folstein SE,McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinicianJ Psychiatr ResYear: 19751218919810.1016/0022-3956(75)90026-61202204|
|32..||McKeith IG,Galasko D,Kosaka K,et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshopNeurologyYear: 199647111311248909416|
|33..||McKhann G,Drachman D,Folstein M,et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's DiseaseNeurologyYear: 1984349399446610841|
|34..||Neary D,Snowden JS,Gustafson L,et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteriaNeurologyYear: 199851154615549855500|
|35..||Scheltens P,Pasquier F,Weerts JG,et al. Qualitative assessment of cerebral atrophy on MRI: inter- and intra-observer reproducibility in dementia and normal agingEur NeurolYear: 199737959910.1159/0001174179058064|
|36..||Landis JR,Koch GG. The measurement of observer agreement for categorical dataBiometricsYear: 19773315917410.2307/2529310843571|
|37..||Galton CJ,Gomez-Anson B,Antoun N,et al. Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementiaJ Neurol Neurosurg PsychiatryYear: 20017016517310.1136/jnnp.70.2.16511160463|
|38..||Wattjes MP,Henneman WJ,Flier WM,et al. Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CTRadiologyYear: 200925317418310.1148/radiol.253108226219635835|
demographic characteristics and imaging measurements per patient group
|Females||20 (53%)~||30 (50%)~||5 (25%)|
|Age (at diagnosis)||65.4 y (7)||66.4 y (10)||62.0 y (5)|
|Duration of symptoms||–||3.2 y (2)||4.7 y (5)|
|MMSEa||29 (20–30)/28 (2)||21 (9–30)/20 (4)* ~||24 (17–30)/25 (4)*|
|MTA||0 (0–3)/0.4 (0.7)||1 (0–4)/1.3 (1.0)*||1 (0–4)/1.2 (1.0)*|
|GCA||0 (0–2)/0.2 (0.5)||1 (0–2)/1.1 (0.7)* ~||1 (0–2)/0.7 (0.7)#|
|PA||0 (0–3)/0.6 (0.7)||0 (0–3)/1.6 (0.9)*†||0 (0–2)/0.8 (0.8)|
Data are presented as median (range)/mean (SD) or N (%)
*p < 0. 01 compared to controls
#p < 0. 05 compared to controls
†p < 0.01 compared to other dementias
~p < 0. 05 compared to other dementias
aMMSE available for 114 patients
AD Alzheimer’s disease, N number of patients, MMSE mini-mental state examination, MTA medial temporal lobe atrophy, GCA global cortical atrophy, y years and PA posterior atrophy
intra- and inter-rater agreement for MTA and PA visual rating scales
|Rater couple 1–2|
|Rater couple 1–3|
|Rater couple 2–3|
Intra-rater agreement was determined in 29 examinations for 2 raters, and inter-rater agreement was determined in 118 examinations for three rater pairings. For weighted-kappa values the degree of agreement was defined according to Landis and Koch  MTA medial temporal lobe atrophy, PA posterior atrophy
Linear regression analysis between visual rating scales (MTA and PA) and MMSE and age
|MMSE||Model 1||−1.4 (0.5)*||−1.7 (0.5)*|
|Model 2||−2.0 (0.5)*||−1.8 (0.5)*|
|Model 3||−1.4 (0.5)*||−1.6 (0.5)*|
|Age||Model 1||3.1 (0.7)*||1.1 (0.8)|
|Model 2||3.1 (0.7)*||1.1 (0.8)|
|Model 3||3.1 (0.8)*||0.1 (0.8)|
Results are presented as linear regression coefficients with standard error, B (SE). Model 1 shows unadjusted associations, in model 2 there was a correction for sex and age in the analysis with the MMSE and correction for sex in the analysis with age. In model 3 both visual rating scales were entered simultaneously, together with the same covariates
*p < 0.01
MTA medial temporal lobe atrophy, PA posterior atrophy and MMSE mini-mental state examination
distribution of the presence of MTA and PA in AD patients and controls
|AD patients||MTA absent||16 (27%)||17 (28%)|
|MTA present||9 (15%)||18 (30%)|
|Controls||MTA absent||33 (88%)||2 (5%)|
|MTA present||3 (8%)||0 (0%)|
|Other dementias||MTA absent||9 (45%)||2 (10%)|
|MTA present||5 (25%)||4 (20%)|
Data are presented as N (%). Scores on the visual rating scales were dichotomized, an average score of >1 was considered abnormal for both rating scales
AD Alzheimer’s disease, MTA medial temporal lobe atrophy, PA posterior atrophy
Keywords: Keywords Alzheimer, Dementia, MRI, Posterior atrophy.
Previous Document: MR-Imaging of teeth and periodontal apparatus: an experimental study comparing high-resolution MRI w...
Next Document: Puf operon sequences and inferred structures of light-harvesting complexes of three closely related ...